Health ❯ Healthcare ❯ Pharmaceuticals

Weight Loss Drugs

Zepbound Wegovy GLP-1 Medications Ozempic Mounjaro GLP-1 Agonists GLP-1 Receptor Agonists Tirzepatide Semaglutide GLP-1 Drugs Clinical Trials CagriSema Eli Lilly and Novo Nordisk Ozempic and Wegovy Novo Nordisk Medicare and Medicaid Coverage Eli Lilly Compounded Medications Bimagrumab Obesity Treatment GLP-1 Therapies GLP-1 Injections Obesity Treatments Costco Discounts Pricing and Accessibility Market Trends Prescription Pricing Retatrutid Wegovy and Ozempic Orforglipron Drug Pricing Ozempic 2.0 FDA Approval Advertising in Healthcare Eli Lilly vs Novo Nordisk GLP-1s Market Competition Mounjaro and Zepbound GLP-1 Compounds Eli Lilly Zepbound Compounded Semaglutide Oral Medications GLP-1 Class GLP-1 Receptor Analogs GLP-1 Treatments Eye Health Medi-Cal Coverage Wegovy and Mounjaro Zepbound vs Wegovy Ozempic and Mounjaro Long-term Effects Ozempic and Tirzepatide Telehealth Patient Management Mounjaro (Tirzepatide) Hims & Hers Health, Inc. Demand and Supply Issues Eli Lilly's Orforglipron

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

The move aims to lower out-of-pocket costs for insured patients whose payments are tied to list prices.

Hims & Hers Shares Fall After Mixed Q4 and Soft Q1 Outlook as GLP‑1 Scrutiny Intensifies

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Eli Lilly Lifts 2025 Guidance After Tirzepatide Fuels Blowout Quarter

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves